Literature DB >> 22364637

Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency.

Kambiz N Alavian1, Steven I Dworetzky, Laura Bonanni, Ping Zhang, Silvio Sacchetti, Maria A Mariggio, Marco Onofrj, Astrid Thomas, Hongmei Li, Jamie E Mangold, Armando P Signore, Ulrike Demarco, Damon R Demady, Panah Nabili, Emma Lazrove, Peter J S Smith, Valentin K Gribkoff, Elizabeth A Jonas.   

Abstract

Cellular stress or injury can result in mitochondrial dysfunction, which has been linked to many chronic neurological disorders including amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD). Stressed and dysfunctional mitochondria exhibit an increase in large conductance mitochondrial membrane currents and a decrease in bioenergetic efficiency. Inefficient energy production puts cells, and particularly neurons, at risk of death when energy demands exceed cellular energy production. Here we show that the candidate ALS drug dexpramipexole (DEX; KNS-760704; ((6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) and cyclosporine A (CSA) inhibited increases in ion conductance in whole rat brain-derived mitochondria induced by calcium or treatment with a proteasome inhibitor, although only CSA inhibited calcium-induced permeability transition in liver-derived mitochondria. In several cell lines, including cortical neurons in culture, DEX significantly decreased oxygen consumption while maintaining or increasing production of adenosine triphosphate (ATP). DEX also normalized the metabolic profile of injured cells and was protective against the cytotoxic effects of proteasome inhibition. These data indicate that DEX increases the efficiency of oxidative phosphorylation, possibly by inhibition of a CSA-sensitive mitochondrial conductance. Copyright Â
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22364637      PMCID: PMC3746080          DOI: 10.1016/j.brainres.2012.01.046

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  57 in total

1.  Zinc-dependent multi-conductance channel activity in mitochondria isolated from ischemic brain.

Authors:  Laura Bonanni; Mushtaque Chachar; Teresa Jover-Mengual; Hongmei Li; Adrienne Jones; Hidenori Yokota; Dimitry Ofengeim; Richard J Flannery; Takahiro Miyawaki; Chang-Hoon Cho; Brian M Polster; Marc Pypaert; J Marie Hardwick; Stefano L Sensi; R Suzanne Zukin; Elizabeth A Jonas
Journal:  J Neurosci       Date:  2006-06-21       Impact factor: 6.167

Review 2.  How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein?

Authors:  Bryan F Shaw; Joan Selverstone Valentine
Journal:  Trends Biochem Sci       Date:  2007-01-05       Impact factor: 13.807

3.  Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride].

Authors:  R Danzeisen; B Schwalenstoecker; F Gillardon; E Buerger; V Krzykalla; K Klinder; L Schild; B Hengerer; A C Ludolph; C Dorner-Ciossek; L Kussmaul
Journal:  J Pharmacol Exp Ther       Date:  2005-09-27       Impact factor: 4.030

Review 4.  Mitochondria in amyotrophic lateral sclerosis: a trigger and a target.

Authors:  Luc Dupuis; Jose-Luis Gonzalez de Aguilar; Hugues Oudart; Marc de Tapia; Luis Barbeito; Jean-Philippe Loeffler
Journal:  Neurodegener Dis       Date:  2004       Impact factor: 2.977

5.  Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects.

Authors:  Michael E Bozik; James L Mather; William G Kramer; Valentin K Gribkoff; Evan W Ingersoll
Journal:  J Clin Pharmacol       Date:  2010-10-19       Impact factor: 3.126

6.  Detection of the mitochondrial apoptosis-induced channel (MAC) and its regulation by Bcl-2 family proteins.

Authors:  Kathleen W Kinnally; Sonia Martinez-Caballero; Laurent M Dejean
Journal:  Curr Protoc Toxicol       Date:  2006-12

Review 7.  Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease.

Authors:  Mark W Dodson; Ming Guo
Journal:  Curr Opin Neurobiol       Date:  2007-05-11       Impact factor: 6.627

8.  Pramipexole protects against MPTP toxicity in non-human primates.

Authors:  Mahmoud M Iravani; Claire O Haddon; J Mark Cooper; Peter Jenner; Anthony H Schapira
Journal:  J Neurochem       Date:  2006-02-08       Impact factor: 5.372

9.  Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F1FO ATP synthase.

Authors:  Kambiz N Alavian; Hongmei Li; Leon Collis; Laura Bonanni; Lu Zeng; Silvio Sacchetti; Emma Lazrove; Panah Nabili; Benjamin Flaherty; Morven Graham; Yingbei Chen; Shanta M Messerli; Maria A Mariggio; Christoph Rahner; Ewan McNay; Gordon C Shore; Peter J S Smith; J Marie Hardwick; Elizabeth A Jonas
Journal:  Nat Cell Biol       Date:  2011-09-18       Impact factor: 28.824

10.  Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential.

Authors:  Ying-Bei Chen; Miguel A Aon; Yi-Te Hsu; Lucian Soane; Xinchen Teng; J Michael McCaffery; Wen-Chih Cheng; Bing Qi; Hongmei Li; Kambiz N Alavian; Margaret Dayhoff-Brannigan; Shifa Zou; Fernando J Pineda; Brian O'Rourke; Young H Ko; Peter L Pedersen; Leonard K Kaczmarek; Elizabeth A Jonas; J Marie Hardwick
Journal:  J Cell Biol       Date:  2011-10-10       Impact factor: 10.539

View more
  16 in total

1.  The mitochondrial complex V-associated large-conductance inner membrane current is regulated by cyclosporine and dexpramipexole.

Authors:  Kambiz N Alavian; Steven I Dworetzky; Laura Bonanni; Ping Zhang; Silvio Sacchetti; Hongmei Li; Armando P Signore; Peter J S Smith; Valentin K Gribkoff; Elizabeth A Jonas
Journal:  Mol Pharmacol       Date:  2014-10-20       Impact factor: 4.436

2.  Dexpramipexole improves bioenergetics and outcome in experimental stroke.

Authors:  Mirko Muzzi; Elisabetta Gerace; Daniela Buonvicino; Elisabetta Coppi; Francesco Resta; Laura Formentini; Riccardo Zecchi; Laura Tigli; Daniele Guasti; Martina Ferri; Emidio Camaioni; Alessio Masi; Domenico E Pellegrini-Giampietro; Guido Mannaioni; Daniele Bani; Anna M Pugliese; Alberto Chiarugi
Journal:  Br J Pharmacol       Date:  2017-05-12       Impact factor: 8.739

3.  Site-specific mitochondrial dysfunction in neurodegeneration.

Authors:  Anežka Vodičková; Shon A Koren; Andrew P Wojtovich
Journal:  Mitochondrion       Date:  2022-02-16       Impact factor: 4.534

4.  Mitochondrial protectant pramipexole prevents sex-specific long-term cognitive impairment from early anaesthesia exposure in rats.

Authors:  A Boscolo; C Ori; J Bennett; B Wiltgen; V Jevtovic-Todorovic
Journal:  Br J Anaesth       Date:  2013-04-24       Impact factor: 9.166

Review 5.  The elusive magic pill: finding effective therapies for mitochondrial disorders.

Authors:  Amy Goldstein; Lynne A Wolfe
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

6.  Neuroprotection induced by dexpramipexole delays disease progression in a mouse model of progressive multiple sclerosis.

Authors:  Daniela Buonvicino; Giuseppe Ranieri; Sara Pratesi; Elisabetta Gerace; Mirko Muzzi; Daniele Guasti; Lorenzo Tofani; Alberto Chiarugi
Journal:  Br J Pharmacol       Date:  2020-04-18       Impact factor: 8.739

Review 7.  Mitochondrial dysfunction in amyotrophic lateral sclerosis - a valid pharmacological target?

Authors:  H Muyderman; T Chen
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

8.  Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease.

Authors:  Wei Zhao; Merina Varghese; Prashant Vempati; Anastasiya Dzhun; Alice Cheng; Jun Wang; Dale Lange; Amanda Bilski; Irene Faravelli; Giulio Maria Pasinetti
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

Review 9.  Mechanisms, models and biomarkers in amyotrophic lateral sclerosis.

Authors:  Martin R Turner; Robert Bowser; Lucie Bruijn; Luc Dupuis; Albert Ludolph; Michael McGrath; Giovanni Manfredi; Nicholas Maragakis; Robert G Miller; Seth L Pullman; Seward B Rutkove; Pamela J Shaw; Jeremy Shefner; Kenneth H Fischbeck
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2013-05       Impact factor: 4.092

10.  Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole.

Authors:  Philippe Corcia; Paul H Gordon
Journal:  Ther Clin Risk Manag       Date:  2012-08-27       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.